Signum Biosciences, Inc. announces today that the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a Small Business Innovation Research (SBIR) Phase IIB grant totaling $3.0 million over 3 years for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis (AD).
Utilizing the funding provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) via the preceding Phase II grant, Signum identified SIG1451 from its isoprenylcysteine (IPC) technology platform as its lead drug candidate for AD. This Phase IIB funding will be used to take SIG1451 through IND-enabling safety/toxicology studies and into the clinic, where Post-IND clinical, chemistry and formulation work will also be performed.
Dr. Eduardo Pérez, CSO stated, “Over the past decade we have built a robust medicinal chemistry and R&D team to mine our IPC library for new therapeutics. Building on the experience and momentum provided by SIG990/DMT210, we believe SIG1451 will provide an important additional, and potentially better, therapeutic option for those suffering from AD.”
Full Press Release